NASDAQ:SBBP
Delisted
Strongbridge Biopharma plc Stock News
$2.00
+0 (+0%)
At Close: May 27, 2022
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
04:05pm, Tuesday, 05'th Oct 2021
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
04:01pm, Tuesday, 05'th Oct 2021
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
04:01pm, Thursday, 23'rd Sep 2021
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Irelan
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
04:01pm, Wednesday, 08'th Sep 2021
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have vo
Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris
Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals
Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates
10:39am, Thursday, 05'th Aug 2021
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
07:30am, Thursday, 05'th Aug 2021
~ Reports KEVEYIS ® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement
07:30am, Monday, 02'nd Aug 2021
DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
08:15am, Thursday, 29'th Jul 2021
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the
Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021
07:30am, Thursday, 29'th Jul 2021
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comme
Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:05pm, Tuesday, 27'th Jul 2021
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~
Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing's Syndrome
04:01pm, Thursday, 03'rd Jun 2021
DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comme
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Strongbridge Biopharma plc - SBBP
07:31am, Saturday, 29'th May 2021
NEW YORK, May 29, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Act
